Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026)

Akebia Therapeutics has reported Current Deferred Revenue over the past 10 years, most recently at $2.7 million for Q4 2025.

  • Quarterly Current Deferred Revenue changed N/A to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.7 million for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue was $2.7 million for Q4 2025 at Akebia Therapeutics, down from $3.9 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $75.8 million in Q1 2022 and troughed at $1.2 million in Q1 2025.
  • The 5-year median for Current Deferred Revenue is $43.3 million (2023), against an average of $35.6 million.
  • Year-over-year, Current Deferred Revenue skyrocketed 323.8% in 2021 and then plummeted 97.18% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $42.4 million in 2021, then increased by 10.98% to $47.0 million in 2022, then decreased by 7.95% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then plummeted by 93.81% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Current Deferred Revenue are $2.7 million (Q4 2025), $3.9 million (Q3 2025), and $5.5 million (Q2 2025).